RxDoctor Payments Data

Woodley Mardy-Davis, MD

Interventional Pain Medicine · Alpharetta, GANPI 1619188505

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,865 of the $11,187 with a category attached, or 61.4%. 23 manufacturers reported payments, led by Medtronic at 59.5% of the total.

$11,187in general payments, 2019–2025

Across 165 payments — averaging $67.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • AbbVie$772
  • Relievant Medsystems, Inc.$684
  • Boston Scientific$655
  • Titan Pharmaceuticals, Inc.$615
  • Abbott$349
  • plus $1K from 17 others

What the payments were for

  • Travel & lodging$4,32239%
  • Food & beverage$6,86561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)68$6,662
AbbVie15$772
Relievant Medsystems, Inc.4$684
Boston Scientific11$655
Titan Pharmaceuticals, Inc.5$615
Abbott8$349
Lilly USA, LLC12$322
Nevro Corp.5$291
Eisai Inc.8$205
Kyowa Kirin, Inc.3$162
Tersera Therapeutics LLC3$69
Teva Pharmaceuticals USA, Inc.3$64
Amgen3$56
Indivior Inc.3$55
Novartis4$48
Orexo US, Inc.2$40
Daiichi Sankyo Inc.2$35
Electronic Waveform Lab, Inc.1$22
Medline Industries LP1$18
Ferring Pharmaceuticals Inc.1$17
Neuronetics, Inc.1$17
Zyla Life Sciences, Inc.1$14
Redhill Biopharma Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,187 in reported general payments places this provider in the 75th percentile of 129 interventional pain medicine providers in Georgia.

See all interventional pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$136,389
Medicare patients
153
Services billed
2,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate48$35,983
NucyntaTapentadol Hcl13$20,252
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen591$16,430
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen506$10,881
OxycontinOxycodone Hcl14$7,167
Morphine Sulfate ErMorphine Sulfate208$3,472
Oxycodone Hcl211$2,946
Fentanyl27$2,333
Methadone Hcl90$1,199
Morphine Sulfate37$981
Buprenorphine Hcl19$678
Pregabalin33$615
Hydromorphone Hcl30$437
Gabapentin20$345
Duloxetine Hcl22$334

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Alpharetta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →